Renal SABR: Implementation of A New Standard of Care.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41539577.
- Also identified by DOI 10.1016/j.ijrobp.2025.12.046.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
SABR , or stereotactic ablative radiation therapy, has emerged as a new standard of care treatment option for localized renal cell carcinoma. Here, we present an accessible, high-yield guide to implementing SABR therapy for renal cell carcinoma. A question-and-answer format was selected for ease of navigation. Common queries around treatment indications and patient selection for SABR planning, delivery, and follow-up are addressed. Succinct, quick-hit answers are supported by relevant, contemporary literature.
Medical subject headings
- Kidney Neoplasms
- Radiosurgery
- Carcinoma, Renal Cell
- Standard of Care